Binks Winks (@Binkswinks1) profile picture
Joined December 2025
Photo by Binks Winks (@Binkswinks1)Photo by Binks Winks (@Binkswinks1)Photo by Binks Winks (@Binkswinks1)Photo by Binks Winks (@Binkswinks1)Photo by Binks Winks (@Binkswinks1)Photo by Binks Winks (@Binkswinks1)Photo by Binks Winks (@Binkswinks1)Photo by Binks Winks (@Binkswinks1)Photo by Binks Winks (@Binkswinks1)Photo by Binks Winks (@Binkswinks1)
Binks Winks retweeted
$DVLT Who gets the earnout if triggered? NYIAX stockholders. Section 6.20 allocates it pro rata by ownership immediately before the merger. Eligible holders receive restricted DVLT shares. Unaccredited holders receive cash. How many NYIAX shares did Gallo own at that moment? 5/5
2
1
3
213
Binks Winks retweeted
$DVLT The 13M earnout had a specific trigger. Under §6.20(a), DVLT or NYIAX had to sign and announce a definitive agreement with a Trading Market, approved by DVLT’s board, within 12 months of closing. As of Nov. 19, I found no public announcement of a qualifying deal. 4/5
1
1
2
191
Binks Winks retweeted
$DVLT What did Gallo pay? If she received fully vested NYIAX shares for services and paid $0, their full fair market value at transfer generally counted as ordinary compensation income under IRC §83(a). Her Form 3 gives the share count. It leaves the acquisition terms open. 3/5
1
1
2
168
Binks Winks retweeted
$DVLT NYIAX’s 2024 SEC filing tied Gallo’s 225,000 restricted stock units and 200,000 options at $4 to an IPO that never closed. Her contract allowed later performance awards. Did she receive one? If so, how many shares, on what date, at what price, and who approved it? 2/5
1
1
3
167
Binks Winks retweeted
Replying to @Binkswinks1
$DVLT Gallo signed the NYIAX merger agreement as CEO. Her Nov. 19 Form 3 reports direct ownership of 4,837,496 DVLT shares. At the 1.41 ratio in the August closing filing, that implies about 3.43M NYIAX shares if all came through the merger. When and how did she acquire them? 1/5
1
1
3
166
Binks Winks retweeted
$DVLT NYIAX’s 2024 filing tied Teri Gallo’s 225,000 RSUs and 200,000 options to its IPO. $DVLT’s 8K put the Aug. 18 merger exchange ratio at ~1.41. Her Nov. 19 Form 3 shows 4,837,496 DVLT shares. If all came from the merger, when and how did she acquire ~3.43M NYIAX shares?
1
1
1
202
Binks Winks retweeted
$DVLT NYIAX’s 2024 SEC filing tied Gallo’s equity awards to an IPO. NYIAX withdrew the offering. Her Nov. 19 Form 3 reports 4,837,496 $DVLT shares. How many came from the NYIAX merger, and if any did, when and on what terms did she acquire the underlying NYIAX shares?
1
1
1
177
Binks Winks retweeted
Replying to @Binkswinks1
$DVLT COO Teri Gallo’s Nov. 19 Form 3 reports direct ownership of 4,837,496 shares as of Nov. 6. She signed the merger agreement as NYIAX CEO. How many of those shares did she receive in the merger, and how did she acquire the rest, if any? The Form 3 gives no breakdown.
1
2
4
252
Let’s step back from the daily noise and look at the real crossroads in front of $DVLT shareholders right now. This isn’t about personalities or social media drama. It is about two completely different futures for this company — the progress being built with the inventor, versus where I genuinely believe this ends up if Brett Moyer and the current board keep the keys. --- PART 1: THE REAL PROGRESS WITH NATE BRADLEY If you ever bought $DVLT for the technology, let’s be honest: you invested in Nate. People with short memories act like nothing was built. Look at what actually exists because of Nate’s vision and execution: • A Deep, Foundational Patent Stack: Nate is a veteran inventor (70+ personal patents, founder of AudioEye, former CTO of Marathon Patent Group) who architected $DVLT’s core ecosystem — DataScore® & DataValue®, the Information Data Exchange® (immutable Digital Twins & NIL), Data Vault Bank®, VerifyU™, ADIO® ultrasonic tech, Sumerian® crypto anchors, WiSA® wireless audio, the allowed Data Futures Platform patent, and patented blockchain anti-short shareholder verification. • Real-World Commercial Foundations: Strategic biotech and medical exchange licensing alliances with Scilex ($SCLX) and Vivasor, real-world asset tokenisation momentum (including insured carbon removal credits with Biochar Now, the Strategic Materials Acquisition Platform / SMAP ecosystem tied to JP3E Holdings, and PharmacyChain™ smart-contract links with DataMeds AI / $MEDS). • Standing Up For Everyday Shareholders: Nate refused to wipe out retail with a brutal reverse split, brought a $90M–$100M financing lifeline to the table before the weekend lockout, hired former SEC enforcement counsel in Delaware, and just made the biggest move yet — formally filing the Delaware Section 228 Written Consent (Schedule 13D/A) alongside Dr. Henry Ji and an aligned Scilex/Vivasor slate to take governance back before December 16. • Crucial Fact on Nasdaq: $DVLT is currently SUSPENDED pending a Nasdaq Hearings Panel appeal — NOT permanently delisted. Putting Nate and an aligned board back in charge means THEY finish the audit cleanup and present the Nasdaq comeback plan, not the faction that drove us onto OTC. --- PART 2: THE FORWARD POSSIBILITIES (WHAT $DVLT CAN STILL BECOME) Nothing in markets is guaranteed — these are forward possibilities, not promises — but follow the breadcrumbs of what hasn’t even been fully switched on yet if Nate and Scilex take the helm: • Live, Revenue-Generating Exchanges: Turning patented data-valuation rails into active Biotech, Medical, Carbon, Strategic Metals, and Real-World Asset exchanges where real assets and anonymised clinical/genomic data are verified and monetised without sacrificing privacy. • A Connected Healthcare & RWA Ecosystem: Uniting non-opioid pain science and deep antibody IP ($SCLX), verified blockchain valuation and exchange infrastructure ($DVLT), and AI-driven pharmacy delivery, smart contracts, and diagnostics ($MEDS) into a joined-up loop the market hasn’t seen before. • True Market Transparency: Rolling out compliant, issuer-sponsored tokenisation and on-chain shareholder verification right as global finance shifts onto blockchain rails — giving pioneering biotechs and everyday retail holders a genuine defence against market abuse. • Real Alignment at the Top: A board backed by major strategic shareholders holding hundreds of millions of shares alongside retail. They don’t win by wiping us out — they only win when the business executes, gets back on Nasdaq, and creates real long-term value. --- PART 3: HOW I BELIEVE THIS PANS OUT IF BRETT MOYER & THIS BOARD STAY (MY OPINION) Look closely at the SEC filings, the recent track record, and the exact wording Moyer’s own board has already put in black and white. If this board survives past December 16, here is how I believe the playbook unfolds step by step:👇
3
3
14
1,115
1. Continued Drift & Missed Deadlines: While telling supporters they are "on top of it", this board has overseen the Nasdaq suspension to OTC and already filed a Form NT 10-Q admitting they missed the Q3 10-Q deadline too. 2. Heavy Dilution + A Brutal Reverse Split: They push through the Streeterville share-cap waiver (flooding hundreds of millions of cheap shares) and execute a harsh 1-for-50 reverse split. Retail share counts get crushed into dust. 3. The CUSIP Reset Gift to Wall Street: A reverse split changes the stock’s 9-digit CUSIP tracking ID, taking the heat off legacy short positions and letting prime brokers sweep old clearing headaches out of sight. Nate’s anti-short mission dies on the spot. 4. The Distressed OTC "Wash-Out & Re-Load" Playbook: Look at who sits on this board and now chairs $DVLT’s Audit Committee — the Abri Capital restructuring team (Christopher Hardt, former CFO of Abri Capital, alongside Jeffrey Tirman), whose previous public vehicle Collective Audience ($CAUD) dropped from Nasdaq to the OTC Expert Market, saw debt swapped into senior preferred equity at the bottom, and had its operating assets carved out into NYIAX while retail stayed trapped in an OTC shell. Once retail is compressed on OTC, restructuring insiders get to write the "rescue" preferred financing at pennies on the dollar. 5. Broken Partnerships & Carved-Out Patents: Read the quiet warning buried on page 8 of Moyer’s own November 6 Form 8-K flagging "the timing and effect of any reverse stock split" AND "the Company’s ability to exit, renegotiate or restructure existing commercial arrangements." Without Nate and Scilex, I believe we see the Scilex and Vivasor biotech partnerships challenged or torn up, and $DVLT’s crown-jewel patent stack (including NYIAX’s exchange patents co-owned with Nasdaq) carved out, licensed off, or sold to legacy Wall Street and Big Tech players — leaving everyday retail investors holding an empty shell. --- THE CHOICE IS RIGHT IN FRONT OF US A restructuring caretaker looks at a patent portfolio and sees spare parts to strip and sell. The inventor sees how every layer locks together to build something historic. One path gives the builder and aligned strategic partners the chance to finish what they started — with retail still at the table. The other path looks like every classic OTC wash-out retail has ever been burned by. I backed the tech. I’m backing the inventor. I’m voting for Nate. $DVLT $SCLX $MEDS
1
9
190
Why I’m voting for Nate Bradley. If you ever invested in $DVLT for the tech, you didn’t invest in a ticker — you invested in the inventor. A restructuring caretaker looks at a patent stack and sees spare parts to carve up. The architect sees how DataScore®, DataValue®, IDE Digital Twins, VerifyU™, ADIO®, Sumerian®, Data Vault Bank®, the Data Futures Platform, and anti-short blockchain verification all lock together. Bring $SCLX onto the board alongside him — with non-opioid pain science, G-MAB™ antibody IP, and $MEDS already bridging in via PharmacyChain™, EinsteinRx™, and QOLPOM™ — and you can see the breadcrumbs of what hasn’t even been built yet: live Biotech & RWA exchanges, a connected healthcare loop, and real market transparency. With Nate & Scilex: the builder finishes the vision and retail keeps its stake. Without them: heavy dilution, a brutal reverse split to bury short headaches, broken deals, and crown-jewel patents stripped away. I backed the tech. I’m backing the inventor. $DVLT $SCLX $MEDS @Datavault_ai @natelliteX
5
7
1
35
1,801
$DVLT I believe Nate may have seen things unfolding over the past several months that raised concerns especially regarding the release of the Bitcoin. If Scilex was such a major issue when it came to receiving the Bitcoin, why would Nate have recommended Henry Ji for the Board of Directors in the first place? Especially when Nate is now trying to gain shareholder support to be voted back onto the board. My gut tells me Nate may be preparing to share some pretty explosive details on social media in the near future. I’m very interested to see what comes out.
4
3
25
2,249
Binks Winks retweeted
New $DVLT video is out. I went through the delayed filings, auditor changes, and the proposed board slate. Also looked into the Scilex connection and how all of this ties together. Quite a few things happening between these two companies. youtube.com/watch?v=QMDlAg1e… $DVLT @Datavault_ai #DVLT
2
2
1
15
3,773
Binks Winks retweeted
🤖 Made with AI
4
4
11
839
Binks Winks retweeted
youtu.be/SXd6dO-Uvb0?si=BpgE… BlackRock is going to need a license to the DVLT portfolios! #rightplacerighttime #freedomtooperate #ai #blockchain #DVLT
🤖 Made with AI
50
17
10
118
25,290
Binks Winks retweeted
More Fuckery: @natelliteX just submitted a SEC diling in regards to @Datavault_ai. Basically.... This filing is a Schedule 13D/A (Amendment No. 4) filed on November 17, 2026, by Nathaniel Bradley (Datavault AI’s former CEO), his spouse Sonia Choi, and EOS Technology Holdings Inc. (where Bradley is CEO and a director). In short, Nathaniel Bradley has launched a formal shareholder takeover/proxy fight via written consent to overhaul Datavault AI’s Board of Directors and reinstall himself as CEO. 1. What Bradley is Trying to Do (The Proposals) Instead of waiting for an annual shareholder meeting, Bradley executed a written consent on November 13, 2026, and is soliciting other shareholders to sign on to five coordinated actions: * Remove 8 Current Directors: Remove without cause Brett Moyer (CFO/Director), Kimberly Briskey, Jeffrey M. Gilbert, Sriram Peruvemba, Christopher R. Hardt, Jeffrey Tirman, Helge Kristensen, and David Howitt—plus anyone appointed to the board after November 12, 2026. * Elect a New 8-Person Board: Fix the board size at eight seats and elect his proposed slate: * Nathaniel Bradley (if not already serving) * Henry Ji (Executive Chairman/CEO of Scilex Holding Company, a major DVLT shareholder) * Dorman Followwill, Yue Alexander Wu, Jay Chun, Stephen Ma, Paul Di Lucia, and Sai Huda * Repeal Recent Bylaw Changes: Undo any bylaw amendments adopted by the current board after September 25, 2025 (a standard move to strip away anti-takeover defenses the board may have put in place). * Control Board Vacancies: Ensure that any board seats left vacant by shareholder removals can only be filled by shareholders, preventing the outgoing board from appointing replacements. * Reclaim the CEO Role: The filing explicitly states that if the board overhaul succeeds, the group intends to seek Bradley's reinstatement as CEO of Datavault AI. 2. Ownership Breakdown & Dilution Context Because Datavault AI’s total outstanding share count expanded to 1,029,489,970 shares as of October 26, 2026, Bradley's group has been diluted down to 2.9% of the company—meaning they are no longer above the 5% beneficial ownership threshold. - EOS Technology Holdings Inc., 13,436,871, Controlled by Nathaniel Bradley (CEO/Director) - Nathaniel Bradley, 10,906,188m. Held personally. - Sonia Choi, 5,804,483. Held personally (Bradley's spouse) | - Total Group Beneficial Ownership, 30,147,542 (2.9%) - Includes an aggregate increase of 10,446,752 shares since Amendment No. 3. Note on Unreleased RSUs: The 2.9% figure excludes 900,000 Restricted Stock Units (RSUs) granted to Bradley under his inducement award agreement (600,000 of which met performance vesting conditions on March 31, 2026, but haven't been released yet, and 300,000 that vest quarterly over 36 months starting December 20, 2025). 3. What Happens Next? * The 60-Day Clock: For Bradley’s proposals to take effect, holders of a majority (>50%) of Datavault AI's outstanding voting shares must sign and deliver written consents within 60 days of the first consent delivery. * Why Henry Ji's Name Matters: Because Bradley’s group only controls 2.9% on its own, they need institutional backing. Nominating Henry Ji strongly signals an alignment with Scilex Holding Company (which previously reported holding ~15.9% of DVLT) and allied entities to rally enough votes to cross the 50% threshold. * Attached Exhibit (EX-99.11): The filing also includes Exhibit 99.11, which contains the formal legal text/documents for the written consent solicitation. ir.datavaultsite.com/sec-fil…
7
5
1
22
2,887